Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA -1.21% 85 Delayed Quote.-5.29%
ROCHE HOLDING LTD. 0.25% 224.55 Delayed Quote.-8.90%
ROCHE HOLDING LTD. 1.33% 191.64 Delayed Quote.-9.12%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
05/17MERCK : Researchers from Merck KGaA Report on Findings in Zika Virus (Mitigating..
AQ
05/17Merck, Pfizer report early data for PD-L1/ALK inhibitor combos
AQ
05/16MERCK : MilliporeSigma to Use Genome Editing in Study of Gut Bacteria to Benefit..
PU
05/15MERCK KGAA : to Host Earnings Call
AC
05/15MERCK KGAA : to Host Earnings Call
AQ
05/15Merck KGaA's Shares Fall After 1Q Results -- Update
DJ
05/15Merck KGaA's 1Q Sales Decline, Dragged by Currency Headwinds
DJ
05/15MERCK : Darmstadt, Germany, Reports a Solid Start to 2018
PU
05/15MERCK KGAA : Slide show Q1 results
CO
05/15MERCK KGAA : 1st quarter results
CO
More news
News from SeekingAlpha
05/15Merck's (MKGAF) Management on Q1 2018 Results - Earnings Call Transcript 
05/15Merck KGaA 2018 Q1 - Results - Earnings Call Slides 
05/15Merck KGaA reports Q1 results 
05/02Merck KGaA to develop abituzumab for CRC with SFJ 
04/20Key events next week - healthcare 
Financials (€)
Sales 2018 15 048 M
EBIT 2018 2 954 M
Net income 2018 1 985 M
Debt 2018 7 759 M
Yield 2018 1,49%
P/E ratio 2018 18,01
P/E ratio 2019 17,61
EV / Sales 2018 1,26x
EV / Sales 2019 1,09x
Capitalization 11 150 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 97,2 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-5.29%13 104
ABBVIE9.59%167 130
KYOWA HAKKO KIRIN CO LTD3.20%11 900
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD71.20%10 237
JAZZ PHARMACEUTICALS PLC0.00%9 900
CONVATEC GROUP9.59%5 985